Hello dear dr

No

https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.sciencedirect.com/science/article/pii/S1876034120304676&ved=2ahUKEwj7rcCFw83qAhUCsaQKHdvZCJ8QFjAAegQIARAB&usg=AOvVaw00lLLdedNUSCBA1p7q-40n

Hi Dr

https://onlinelibrary.wiley.com/doi/full/10.1111/trf.15831

May be

Hi Dr. Anwar

https://apps.who.int/iris/rest/bitstreams/1272656/retrieve#:~:text=The%20risk%20of%20transmission%20of,theoretical%20and%20likely%20minimal.

Certainly

Maintaining a safe and adequate blood supply during the

pandemic outbreak of coronavirus disease (COVID-19)

Interim guidance

20 March 2020

Background

This document provides interim guidance on the management

of the blood supply in response to the pandemic outbreak of

coronavirus disease (COVID-19). It is intended for blood

services, national health authorities, and others responsible

for the provision of blood and blood components and

integration of the blood system within the public health

system. WHO will continue to update this guidance as new

information becomes available.

This document is adapted from the WHO Guidance for

National Blood Services on Protecting the Blood Supply

During Infectious Disease Outbreaks1

and risk assessment

publications on COVID-19 from regional

networks/institutions.

2-4

General considerations

The COVID-19 virus outbreak is primarily transmitted by the

respiratory route and theoretically by transfusions. The

epidemic has the potential to reduce the supply of blood and

blood components and adversely affect blood system

activities. Blood services should therefore take steps to assess,

plan, and respond appropriately and proportionately.

The risk of transmission of COVID-19 through transfusion of

blood and components is now only theoretical and likely

minimal. But experience with outbreaks of other

coronaviruses suggests that there will be significant impact

on blood supplies through reduced blood donation.

5-7

Effective and accurate data-driven risk assessment is

necessary to determine the most appropriate and

proportionate action, taking into consideration: a) the extent

of COVID-19 spread in the country or geographical area;

b) level of community circulation (limited and contained vs

widespread and sustained); c) local epidemiology; d) risk of

transfusion transmission in context of overall burden of

disease; e) quality of health care system; f) public health

response; blood supply sufficiency; g) operational impacts;

and h) cost effectiveness of blood safety interventions in

reducing disease morbidity in relation to the overall situation

in the country.

Blood services must be prepared to move quickly in response

to changes, during which blood sufficiency is most likely to

be affected. A national rather than sub-national or local

approach should be adopted for coherence and coordination

and to ensure public confidence in blood safety and supply.

Blood services should be included in the national outbreak

response, through experts linked to the national emergency

response team. Blood services should activate their

emergency response plans. Networks of cooperating blood

services across regions can help maintain the availability of

blood and blood components.

1. Mitigating the potential risk of

transmission through the transfusion of

blood and blood components

Respiratory viruses have never been reported to be

transmitted through blood or blood components; therefore,

any potential risk of transmission by transfusion of blood

collected from asymptomatic individuals is theoretical. Any

actions taken to mitigate risk are therefore precautionary.

Options include donor education, self-deferral or deferral of

at-risk donors, quarantine of blood components, retrieval of

in-date products based on a report of post-donation illness in

the donor, screening of donations using laboratory tests, and

pathogen reduction:

a. Potential donors should be educated about the need

to self-defer based on risk factors for COVID-19 or

feeling unwell. Current donor screening measures

excluding symptomatic individuals who are unwell

or with signs and symptoms of fever and respiratory

disease (such as cough or breathlessness) must be

strictly complied with. Persons who donate should

inform the blood centre immediately if they develop

a respiratory illness within 28 days of donation.

b. Persons who have fully recovered from confirmed

COVID-19, those with possible direct exposure to

COVID-19 from a confirmed case, and those who

have travelled from areas with ongoing community

transmission should refrain from blood donation for

at least 28 days. This may take the form of self￾deferral or mandatory deferral. In the event of

widespread transmission, donor restrictions based

on definitions of exposure risk and duration of

deferral may need to be reduced to fit the local

situations so as not to affect availability of blood for

critical transfusion therapy.

c. Quarantine of components with delayed release

based on absence of a reported subsequent illness in

the donor is an option in the event of widespread and

sustained transmission. But this is difficult to

implement and disrupts existing processes and

workflows, leading to greater potential for errors.

Release of blood into available inventory is delayed,

and quarantine of platelets is particularly

problematic given their short shelf-life.

May be.

May be

Hi Dr.

The risk of transmission of COVID-19 through transfusion of blood and components is now only theoretical and likely minimal.

https://apps.who.int/iris/rest/bitstreams/1272656/retrieve#:~:text=The%20risk%20of%20transmission%20of,theoretical%20and%20likely%20minimal.

No till now

May be .

May be

Till now there is no evidence

No,

there is no evidence

No

Good afternoon Dr.

May be

Hi Dr.

No

Actually, I don't know

Respiratory viruses, in general, are not known to be transmitted by blood transfusion, and there have been no reported cases of transfusion-transmitted coronavirus.

Article Is SARS-CoV-2 transfusion transmitted?

SARS-CoV-2 has not been identified as a transfusion transmissible virus and viremia has only been diagnosed in serious patients who would not be allowed for blood donation.

Source:

Article Blood safety in SARS-CoV-2 infection

Please have a look at the link below:

Article COVID-19 transmission and blood transfusion: A case report

The recent outbreak of the novel coronavirus disease 2019 (COVID-19) has been labelled as a pandemic by the World Health Organization. Although person-to-person transmission of the etiologic agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been confirmed, it is not known whether COVID-19 may be transmitted by blood transfusion. Notwithstanding the urgent requirement of blood, it is critical to know whether the SARS-CoV-2 virus can be transmitted by blood transfusion because many individuals may be asymptomatic carriers and may donate blood. Several cases in which specific viral RNA could be detected in the serum from patients with COVID-19 have already been reported; these findings suggest that blood donation may be an unexplored route of transmission. However, the American Association of Blood Banks and Centers for Disease Control and Prevention have not recommended any specific SARS-CoV-2-related actions to be taken at blood collection centres at this time. In this report, we describe a case of a 21-year-old man with very severe aplastic anaemia who received apheresis platelet transfusion from an individual who was subsequently diagnosed with COVID-19. Our patient tested negative for COVID-19 and is awaiting allogeneic stem cell transplantation.

Dear Huda Hadi Al-Hasnawy ,

Thank you very much for your contribution.

Dear Harasit Kumar Paul ,

Thank you very much for your contribution.

Dear Arvind Singh ,

Thank you very much for your contribution.

Dear Hadaf Kadhim ,

Thank you very much for your contribution.

Dear Hiba J. Hamza ,

Thank you very much for your contribution.

Dear Yazi Abdullah Jassim ,

Thank you very much for your contribution.

Dear Taif Majid Abdulhussein ,

Thank you very much for your contribution.

Dear Assist.Prof.Dr. Mays Hadi Jebur ,

Thank you very much for your contribution.

Dear Foad Alzoughool ,

Thank you very much for your contribution.

Dear Sura Aldewachi ,

Thank you very much for your contribution.

Dear Batool Shakir Abed Almjalawi ,

Thank you very much for your contribution.

Dear Samah Ahmed Kadhum Al-jebory ,

Thank you very much for your contribution.

Dear Anmar Aldewachi ,

Thank you very much for your contribution.

Dear Lubna Abdulazeem ,

Thank you very much for your contribution.

Dear Ahmed Abdulkareem Almuteari ,

Thank you very much for your contribution.

Dear Alaa Shahid Jassim Al-Bdery ,

Thank you very much for your contribution.

Dear Hawraa Natiq Kabroot Al-Fatlawy ,

Thank you very much for your contribution.

Dear Ali Kifah Kadhum ,

Thank you very much for your contribution.

Dear Basim Mohammed Hanon ,

Thank you very much for your contribution.

Dear Ayser Ashour ,

Thank you very much for your contribution.

This virus stay inside cells that has ACE 2 receptor and present in many tissues like endothelial vessle wall but not in blood corpusles, so not transmitted by blood transfusion.

Dear Nada Khazal K. Hindi ,

Thank you very much for your contribution.

Dear Ziad Hazim Deleme ,

Thank you very much for your contribution.

No, I disagree.

till now No

No, and i agree with the detail explanation of Ziad Hazim Deleme.

Yes, May be.

Dear D. Taghreid Khudhur ,

Thank you very much for your contribution.

Dear Isa Baba Koki ,

Thank you very much for your contribution.

Dear Mazin H Al-Hawaz ,

Thank you very much for your contribution.

Dear Ronald Gomeseria ,

Thank you very much for your contribution.

No

Hi Dr. No

No

No

Dear Taif Majid Abdulhussein ,

Thank you very much for your contribution.

Dear Noor Mahdi

Thank you very much for your contribution.

Dear Anmar Aldewachi ,

Thank you very much for your contribution.

Dear Saad Abd Al-Aziz ,

Thank you very much for your contribution.

Dear Salim Hussein Hassan ,

Thank you very much for your contribution.

No

Dear Saade Abdalkareem Jasim ,

Thank you very much for your contribution.

Havent been proven yet

The coagulopathy chagnes that seen during COVID19 were related to immune eespose rather than the virus itself

No

Dear Entedar Alioy Alsaadi ,

Thank you very much for your contribution.

Dear Fadyia Mahdi Alameedy ,

Thank you very much for your contribution.

Thank you for this prop up question Anwar A. Abdulla Anwar A. Abdulla but i don't know why the general no on this. Has it been proven scientifically yet? Could the coagulopathy changes seen in COVID19 related to immunomodulator be a thing of concern in transfusion therapy? Could the antigen-antibody response overwhelm the system causing more damage? These and more should not be neglected. Thank you.

Dear Ali Sassi ,

Thank you very much for your contribution and information.

A number of published studies report that the RNA of SARS‐CoV‐2, the virus causing pandemic COVID‐19, is detected in the blood, plasma, or serum of infected people. 1-3 Unsurprisingly, some of these reports include RNA detection in blood donors.

Dear Ban M. S. Saeed ,

Thank you very much for your contribution and information.

Almost articles published are changing the results obtained from time to time that means that all results maybe suggestions only, thank you for your nice question. Best regards

Dear Hermann Gruenwald ,

Thank you very much for your contribution and information.

Dear Shaker A.N. Al-Jadaan ,

Thank you very much for your contribution and information.

Dear Saad Msc ,

Thank you very much for your contribution and information.

Curiously, there is no evidence in this regard -especially because those positive in PCRs and Covid-19 patients are discarded as donors-; However, I would not advise -except for life or death- a transfusion with inherited or blood from a Covid-19 patient.

Dear Dr. Francisco Javier Gala ,

Thank you very much for your contribution and information.

Thanks to you, dear Anwar A.Abdulla.

The following study conclude that there is limited evidence of transfusion transmission of SARS-CoV-2 via human blood products.

Article No evidence of SARS-CoV-2 transmission through transfusion o...

The following study conclude that the risk of transfusion transmission of SARS-CoV-2 is negligible.

Article Low risk of SARS-CoV-2 in blood transfusion